Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for ion channels.


 

Fig. 1. The screening workflow of Receptor.AI

This includes extensive molecular simulations of the ion channel in its native membrane environment, in open, closed, and inactivated forms, paired with ensemble virtual screening that factors in conformational mobility in each state. Tentative binding pockets are considered in the pore, the gating region, and allosteric areas to capture the full range of mechanisms of action.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P35498

UPID:
SCN1A_HUMAN

ALTERNATIVE NAMES:
Sodium channel protein brain I subunit alpha; Sodium channel protein type I subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.1

ALTERNATIVE UPACC:
P35498; E9PG49; Q16172; Q585T7; Q8IUJ6; Q96LA3; Q9C008

BACKGROUND:
Sodium channel protein type 1 subunit alpha, or Nav1.1, is essential for the proper functioning of excitable membranes, facilitating sodium ion flow in response to voltage changes. This action is critical for neurotransmitter release and pain perception, underscoring the protein's importance in neural communication and sensory response.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Nav1.1 could open doors to potential therapeutic strategies. Its association with conditions like Migraine, familial hemiplegic, 3, and Febrile seizures, familial, 3A, underscores its therapeutic relevance. Targeting Nav1.1 could lead to novel treatments for a range of neurological diseases, offering hope for patients and advancing neurological research.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.